218 Press Releases found

Memorial Sloan Kettering Cancer Center Researchers Publish Landmark “Basket Study”

Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.

  • Wednesday, August 19, 2015

Lehigh Valley Health Network to Join Memorial Sloan Kettering Cancer Alliance

Memorial Sloan Kettering Cancer Center (MSK) and Lehigh Valley Health Network (LVHN) announced today the beginning of a unique and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and highest-caliber cancer care.

  • Tuesday, August 4, 2015

Memorial Sloan Kettering Launches New Lung Cancer Center Dedicated to Innovative Research

A new lung cancer research center has been created at Memorial Sloan Kettering Cancer Center (MSK). The Fiona and Stanley Druckenmiller Center for Lung Cancer Research (DCLCR) is a multidisciplinary research initiative dedicated to developing innovative and more-effective treatments for people with lung cancer.

  • Thursday, July 9, 2015

First Winners of Tri-Institutional Breakout Awards Announced

Six young scientists at Memorial Sloan Kettering Cancer Center, Rockefeller University, and Weill Cornell Medical College have been named the inaugural winners of a new prize established to recognize postdoctoral investigators in the life sciences. The Tri-Institutional Breakout Awards for Junior Investigators, which include a $25,000 prize for each recipient, were established by three Tri-Institutional winners of the 2013 Breakthrough Prize in Life Science — one from each of the three institutions — with additional financial support from the institutions themselves.

  • Monday, June 15, 2015

Pivotal Results from Phase III Trial Show Combination of Ipilimumab and Nivolumab or Nivolumab Alone Increase Progression-Free Survival in Advanced Melanoma Patients

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering simultaneously presented today at the American Society of Clinical Oncology annual meeting and published online in the New England Journal of Medicine.

  • Sunday, May 31, 2015

Large International Study Is Advancing Precision Medicine for Men with Advanced Prostate Cancer

An international collaboration of researchers is advancing precision medicine for men with advanced prostate cancer.

  • Thursday, May 21, 2015

Memorial Sloan Kettering Cancer Center Receives Record Gift of $150 million from David Koch for Innovative Patient Care Facility

Memorial Sloan Kettering Cancer Center announced that it has received the largest gift in its history, a commitment of $150 million from long-time MSK board member David H. Koch. This unprecedented contribution will transform cancer care with a state-of-the-art outpatient medical facility to be known as The David H. Koch Center for Cancer Care. The new center will provide the most advanced cancer treatments in a dynamic space designed with the needs of patients firmly in mind.

  • Wednesday, May 20, 2015

Memorial Sloan Kettering Cancer Center “Specializes in You” with an Innovative and Personalized Digital Landscape

Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for (Memorial Sloan Kettering Cancer Center) and (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.

  • Tuesday, May 5, 2015

Two Promising Memorial Sloan Kettering Studies Featured at American Association for Cancer Research Annual Meeting

Two encouraging Memorial Sloan Kettering Cancer Center (MSK) studies were featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program.

  • Tuesday, April 21, 2015

Research Proves Combination Immunotherapy Significantly More Effective than Ipilimumab Alone for Patients with Advanced Melanoma

Positive results from a clinical trial published in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab (Yervoy) and nivolumab (Opdivo), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.

  • Monday, April 20, 2015